Cargando…

Why we need easy access to all data from all clinical trials and how to accomplish it

International calls for registering all trials involving humans and for sharing the results, and sometimes also the raw data and the trial protocols, have increased in recent years. Such calls have come, for example, from the Organization for Economic Cooperation and Development (OECD), the World He...

Descripción completa

Detalles Bibliográficos
Autor principal: Gøtzsche, Peter C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264537/
https://www.ncbi.nlm.nih.gov/pubmed/22112900
http://dx.doi.org/10.1186/1745-6215-12-249
_version_ 1782221981344595968
author Gøtzsche, Peter C
author_facet Gøtzsche, Peter C
author_sort Gøtzsche, Peter C
collection PubMed
description International calls for registering all trials involving humans and for sharing the results, and sometimes also the raw data and the trial protocols, have increased in recent years. Such calls have come, for example, from the Organization for Economic Cooperation and Development (OECD), the World Health Organization (WHO), the US National Institutes of Heath, the US Congress, the European Commission, the European ombudsman, journal editors, The Cochrane Collaboration, and several funders, for example the UK Medical Research Council, the Wellcome Trust, the Bill and Melinda Gates Foundation and the Hewlett Foundation. Calls for data sharing have mostly been restricted to publicly-funded research, but I argue that the distinction between publicly-funded and industry-funded research is an artificial and irrelevant one, as the interests of the patients must override commercial interests. I also argue why it is a moral imperative to render all results from all trials involving humans, also healthy volunteers, publicly available. Respect for trial participants who often run a personal and unknown risk by participating in trials requires that they - and therefore also the society at large that they represent - be seen as the ultimate owners of trial data. Data sharing would lead to tremendous benefits for patients, progress in science, and rational use of healthcare resources based on evidence we can trust. The harmful consequences are minor compared to the benefits. It has been amply documented that the current situation, with selective reporting of favorable research and biased data analyses being the norm rather than the exception, is harmful to patients and has led to the death of tens of thousands of patients that could have been avoided. National and supranational legislation is needed to make data sharing happen as guidelines and other voluntary agreements do not work. I propose the contents of such legislation and of appropriate sanctions to hold accountable those who refuse to share their data.
format Online
Article
Text
id pubmed-3264537
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32645372012-01-24 Why we need easy access to all data from all clinical trials and how to accomplish it Gøtzsche, Peter C Trials Commentary International calls for registering all trials involving humans and for sharing the results, and sometimes also the raw data and the trial protocols, have increased in recent years. Such calls have come, for example, from the Organization for Economic Cooperation and Development (OECD), the World Health Organization (WHO), the US National Institutes of Heath, the US Congress, the European Commission, the European ombudsman, journal editors, The Cochrane Collaboration, and several funders, for example the UK Medical Research Council, the Wellcome Trust, the Bill and Melinda Gates Foundation and the Hewlett Foundation. Calls for data sharing have mostly been restricted to publicly-funded research, but I argue that the distinction between publicly-funded and industry-funded research is an artificial and irrelevant one, as the interests of the patients must override commercial interests. I also argue why it is a moral imperative to render all results from all trials involving humans, also healthy volunteers, publicly available. Respect for trial participants who often run a personal and unknown risk by participating in trials requires that they - and therefore also the society at large that they represent - be seen as the ultimate owners of trial data. Data sharing would lead to tremendous benefits for patients, progress in science, and rational use of healthcare resources based on evidence we can trust. The harmful consequences are minor compared to the benefits. It has been amply documented that the current situation, with selective reporting of favorable research and biased data analyses being the norm rather than the exception, is harmful to patients and has led to the death of tens of thousands of patients that could have been avoided. National and supranational legislation is needed to make data sharing happen as guidelines and other voluntary agreements do not work. I propose the contents of such legislation and of appropriate sanctions to hold accountable those who refuse to share their data. BioMed Central 2011-11-23 /pmc/articles/PMC3264537/ /pubmed/22112900 http://dx.doi.org/10.1186/1745-6215-12-249 Text en Copyright ©2011 Gøtzsche; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Gøtzsche, Peter C
Why we need easy access to all data from all clinical trials and how to accomplish it
title Why we need easy access to all data from all clinical trials and how to accomplish it
title_full Why we need easy access to all data from all clinical trials and how to accomplish it
title_fullStr Why we need easy access to all data from all clinical trials and how to accomplish it
title_full_unstemmed Why we need easy access to all data from all clinical trials and how to accomplish it
title_short Why we need easy access to all data from all clinical trials and how to accomplish it
title_sort why we need easy access to all data from all clinical trials and how to accomplish it
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264537/
https://www.ncbi.nlm.nih.gov/pubmed/22112900
http://dx.doi.org/10.1186/1745-6215-12-249
work_keys_str_mv AT gøtzschepeterc whyweneedeasyaccesstoalldatafromallclinicaltrialsandhowtoaccomplishit